In the evolving landscape of pharmaceutical intermediates, the demand for high-purity compounds like 96 31 1 (represented by the chemical utility of Ornithine Aspartate) has become pivotal for advancing metabolic health treatments. As global healthcare systems shift toward more targeted therapies, understanding the synthesis and application of these specialized salts is essential for researchers and manufacturers aiming to optimize patient outcomes.
The global pharmaceutical industry faces the constant challenge of balancing high-yield production with stringent purity standards, a gap that 96 31 1 helps bridge through advanced custom synthesis. By integrating GMP-certified processes and CFDA approvals, suppliers can ensure that the molecular integrity of L-ornithine L-aspartate is maintained from the gram scale to multi-ton commercial production.
Ultimately, the strategic importance of 96 31 1 lies in its role as a critical building block for APIs, facilitating the development of medications that address complex liver and neurological dysfunctions. For biotech firms and research institutions, accessing a stable and scalable supply of this intermediate is not just a procurement necessity but a catalyst for medical innovation.
The Chemical Profile of 96 31 1
The compound identified within the context of 96 31 1 is technically known as Ornithine Aspartate (L-ornithine L-aspartate salt), characterized by the molecular formula C9H18N3O6 and a molecular weight of 264.256. This specific intermediate is designed to serve as a precursor in the manufacture of pharmaceutical agents, leveraging its unique amino acid salt structure to enhance bioavailability and therapeutic efficacy.
From a structural perspective, 96 31 1 operates as a combination of L-ornithine and L-aspartic acid, which are essential for the urea cycle and ammonia detoxification. Its chemical stability and solubility make it an ideal candidate for both injectable and oral pharmaceutical formulations, provided it is synthesized under strict GMP conditions to avoid impurities.
Global Industrial Relevance of 96 31 1
On a global scale, the industrial demand for 96 31 1 is driven by the rising prevalence of chronic liver diseases and metabolic disorders. As healthcare standards harmonize under ISO and other international guidelines, the need for consistent, high-purity pharmaceutical intermediates has surged, pushing manufacturers to adopt more rigorous quality control systems.
The primary challenge in the global supply chain for 96 31 1 is the ability to scale production from R&D grams to industrial tons without compromising the purity profile. This is particularly critical for API manufacturers who require exact specifications to meet CFDA and other regulatory approvals, ensuring that the end-product is safe for human consumption.
Furthermore, the integration of 96 31 1 into the pharmaceutical pipeline allows for more efficient custom synthesis of specialized chemicals. By partnering with leading suppliers who possess strong in-house R&D capabilities, biotech firms can accelerate their time-to-market for new drug candidates targeting the musculoskeletal and nervous systems.
Synthesis Standards for 96 31 1
The synthesis of 96 31 1 requires a precise balance of stoichiometric ratios between L-ornithine and L-aspartic acid. Achieving the correct salt form is essential for the compound's pharmacological activity, requiring advanced purification techniques such as recrystallization to ensure the removal of any unreacted precursors.
For 96 31 1 to be viable for pharmaceutical use, it must adhere to GMP (Good Manufacturing Practice) certifications. This involves comprehensive documentation of every step in the production process, from the sourcing of raw materials to the final packaging in glass vials or bulk bottles, ensuring full traceability.
Modern R&D systems have enabled the custom synthesis of 96 31 1 with enhanced stability. By utilizing specialized catalysts and controlled temperature environments, manufacturers can now produce reference compounds that serve as gold standards for universities and research institutions worldwide.
Performance Metrics of 96 31 1
Evaluating the efficacy of 96 31 1 involves analyzing several key performance indicators, including solubility, purity levels, and stability under various storage conditions. These metrics are crucial for determining the suitability of the intermediate for specific API applications, such as those used in the treatment of hepatic encephalopathy.
When compared to alternative synthesis methods, the high-purity approach to 96 31 1 shows superior results in terms of yield and cost-efficiency over long-term production cycles. The following data illustrates the comparative rating of different production approaches used to achieve the desired specifications.
Production Efficiency Ratings for 96 31 1
Practical Applications of 96 31 1
The primary application of 96 31 1 is found in the pharmaceutical industry, where it acts as a key ingredient for medications treating liver dysfunction. By facilitating the removal of ammonia from the bloodstream, Ornithine Aspartate helps in managing symptoms of hepatic failure, making it a vital component in clinical settings.
Beyond direct therapeutic use, 96 31 1 is widely utilized by research institutions and biotech firms as a reference compound for new reagent development. Its role in custom synthesis allows for the creation of advanced pharmaceutical intermediates that target various systemic classes, including the nervous and musculoskeletal systems.
Long-term Value and Stability of 96 31 1
The long-term value of investing in high-grade 96 31 1 lies in its reliability and consistency. For pharmaceutical companies, using an intermediate with a proven purity profile reduces the risk of batch failure during the final API synthesis, thereby saving significant costs in waste management and regulatory delays.
From a sustainability perspective, optimized production routes for 96 31 1 minimize the use of harmful solvents and maximize atom economy. This alignment with "Green Chemistry" principles ensures that the manufacture of L-ornithine L-aspartate remains eco-friendly while meeting the growing global demand.
Moreover, the trust established through GMP and CFDA certifications provides a layer of security for international trade. When biotech firms source 96 31 1 from a supplier with a mature R&D system, they are not just buying a chemical, but a guarantee of quality that supports the dignity and safety of the end patient.
Future Innovations in 96 31 1 Production
Looking ahead, the production of 96 31 1 is expected to integrate more automation and digital transformation. The use of AI-driven synthesis planning can optimize the reaction conditions in real-time, further increasing the purity and yield of L-ornithine L-aspartate while reducing human error.
Another promising trend is the shift toward biocatalysis for the synthesis of 96 31 1. By employing engineered enzymes, manufacturers may be able to produce these amino acid salts at lower temperatures and pressures, significantly reducing the carbon footprint of the pharmaceutical intermediate industry.
As personalized medicine grows, the demand for custom synthesis of 96 31 1 derivatives will likely increase. This will require suppliers to evolve their capabilities, moving from bulk production to highly specific, small-batch specialized chemicals tailored to the unique genetic profiles of patient populations.
Comparative Analysis of 96 31 1 Production Standards
| Production Grade |
Purity Level (%) |
Certification |
Primary Use Case |
| GMP Pharmaceutical |
>99.5% |
CFDA/GMP |
Direct API Manufacturing |
| Research Grade |
98.0% - 99.0% |
ISO 9001 |
University Lab Testing |
| Custom Synthesis |
Variable |
Client Specific |
New Reagent Development |
| Industrial Bulk |
97.0% - 98.5% |
Industry Std |
Generic Intermediate |
| Reference Standard |
>99.9% |
CoA Certified |
Analytical Calibration |
| Pilot Scale |
99.0% |
Internal QA |
Feasibility Studies |
FAQS
The primary use of 96 31 1, specifically Ornithine Aspartate, is as a pharmaceutical intermediate for the production of medications used to treat liver disorders and ammonia toxicity. It serves as a critical building block for APIs that help detoxify the body, particularly in patients with hepatic failure.
GMP certification ensures that 96 31 1 is produced under strict quality control guidelines. This minimizes the risk of contamination and ensures batch-to-batch consistency, which is essential for regulatory approval (such as CFDA) and patient safety in pharmaceutical applications.
Yes, leading suppliers like Kunxiangda specialize in the custom synthesis of 96 31 1. They offer production capabilities ranging from a few grams for R&D purposes to multi-ton quantities for full-scale commercial pharmaceutical manufacturing.
To maintain the integrity of 96 31 1, it should be stored in a cool, dry place, typically in airtight containers such as glass vials or high-density plastic bottles to prevent moisture absorption and degradation of the amino acid salt.
As an amino acid salt, 96 31 1 is generally compatible with other water-soluble pharmaceutical intermediates. However, compatibility depends on the specific chemical environment and pH of the final formulation, requiring careful R&D testing.
Research institutions can import 96 31 1 by partnering with certified suppliers who provide comprehensive documentation, including Certificates of Analysis (CoA) and Material Safety Data Sheets (MSDS), ensuring compliance with international customs and health regulations.
Conclusion
The synthesis and application of 96 31 1 (Ornithine Aspartate) represent a critical intersection of chemical engineering and medical necessity. From its role in ammonia detoxification to its necessity as a GMP-certified intermediate, this compound continues to provide immense value to the pharmaceutical supply chain, ensuring that high-purity APIs are accessible for treating complex metabolic conditions.
As the industry moves toward greener synthesis and AI-optimized production, the significance of 96 31 1 will only grow. We suggest that pharmaceutical firms and biotech organizations prioritize partnerships with suppliers who offer both custom synthesis flexibility and rigorous regulatory compliance to ensure long-term stability and innovation. Visit our website: www.kxdchem.com
